Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zampilimab
- Development stage
- Phase 2
- Lead developer
- UCB
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Zampilimab is a humanized monoclonal antibody that targets and inhibits transglutaminase 2 (TG2), an enzyme implicated in the pathogenesis of fibrotic diseases. By inhibiting TG2-mediated crosslinking of extracellular matrix proteins, zampilimab aims to reduce or reverse fibrosis. It has been investigated primarily for chronic kidney disease (including chronic allograft injury after kidney transplantation) and idiopathic pulmonary fibrosis (IPF). Zampilimab was originally developed by UCB and later licensed globally to Chiesi for further development and commercialization as a potential anti-fibrotic therapy[1][3][4][5][7].
- Other names
- hDC1hDC-1hDC 1
02
Targets
TGM2 (Tissue Transglutaminase 2)
Beyond the preview
Go deeper on Zampilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zampilimab.